nach oben

International Journal of Colorectal Disease

Erschienen in:

01.05.2005 | Review

The role of the insulin-like growth factor system in colorectal cancer: review of current knowledge

verfasst von: Rajaraman Durai, Wenxuan Yang, Sharmila Gupta, Alexander M. Seifalian, Marc C. Winslet

Erschienen in: International Journal of Colorectal Disease | Ausgabe 3/2005

Einloggen, um Zugang zu erhalten

Abstract

Background

The insulin-like growth factor system, which includes insulin-like growth factors (IGF-I and IGF-II), IGF receptors (IGF-IR and IGF-IIR) and IGF binding proteins (IGFBPs), plays an important role in epithelial growth, anti-apoptosis and mitogenesis. There is a growing body of evidence showing that IGFs control growth and proliferation of several types of cancer. This review introduces the latest information on the biology of the IGF system and its pathophysiological role in the development of colorectal cancer.

Discussion

The growth promoting effects of IGF-I and IGF-II on cancer cells are mediated through the IGF-IR, which is a tyrosine kinase and cancer cells with a strong tendency to metastasise have a higher expression of the IGF-IR. Most of the IGFs in circulation are bound to the IGFBPs, which regulate the bioavailability of the IGFs. All IGFBPs inhibit IGF action by high affinity binding, while some of them also potentiate the effects of IGFs. Colon cancer cells produce specific proteases that degrade the IGFBP so that the IGF will be free to act on the cancer cell in an autocrine manner. Therefore, the IGFBPs play a crucial role in the development of the cancer.

Conclusion

The current knowledge about the link between IGFs and colon cancer is mainly based on in vitro investigations. Further in vivo study is needed to understand the exact role of the IGF system, especially its binding proteins, so that they can be manipulated for the prevention and treatment of colorectal cancer.

Singh P, Dai B, Dhruva B, Widen SG (1994) Episomal expression of sense and antisense insulin-like growth factor (IGF)-binding protein-4 complementary DNA alters the mitogenic response of a human colon cancer cell line (HT-29) by mechanisms that are independent of and dependent upon IGF-I. Cancer Res 54:6563–6570

Kim EJ, Schaffer BS, Kang YH, MacDonald RG, Park JH (2002) Decreased production of insulin-like growth factor-binding protein (IGFBP)-6 by transfection of colon cancer cells with an antisense IGFBP-6 cDNA construct leads to stimulation of cell proliferation. J Gastroenterol Hepatol 17:563–570CrossRef

Midgley R, Kerr D (1999) Colorectal cancer. Lancet 353:391–399CrossRefPubMed

Boyle P, Langman JS (2000) ABC of colorectal cancer: epidemiology. BMJ 321:805–808CrossRef

Szepeshazi K, Schally AV, Groot K, Armatis P, Halmos G, Herbert F, Szende B, Varga JL, Zarandi M (2000) Antagonists of growth hormone-releasing hormone (GH-RH) inhibit IGF-II production and growth of HT-29 human colon cancers. Br J Cancer 82:1724–1731CrossRef

Pollak M (2000) Insulin-like growth factor physiology and cancer risk. Eur J Cancer 36:1224–1228CrossRef

Grimberg A, Cohen P (2000) Role of Insulin-like growth factors and their binding proteins in growth control and carcinogenesis. J Cell Physiol 183:1–9

Hallberg LM, Ikeno Y, Englander E, George H (2000) Effects of aging and caloric restriction on IGF-I, IGF-I receptor, IGFBP-3 and IGFBP-4 gene expression in the rat stomach and colon. Regul Pept 89:37–44CrossRef

Leng SL, Leeding KS, Whitehead RH, Bach LA (2001) Insulin-like growth factor (IGF)-binding protein-6 inhibits IGF-II-induced but not basal proliferation and adhesion of LIM 1215 colon cancer cells. Mol Cell Endocrinol 174:121–127CrossRef

10.

Moschos SJ, Mantzoros CS (2002) The role of the IGF system in cancer: from basic to clinical studies and clinical applications. Oncology 63:317–332

11.

Zhou R, Diehl D, Hoeflich A, Lahm H, Wolf E (2003) IGF-binding protein-4: biochemical characteristics and functional consequences. J Endocrinol 178:177–193PubMed

12.

Yu H, Rohan T (2000) Role of the insulin-like growth factor family in cancer development and progression. J Natl Cancer Inst 92:1472–1489CrossRef

13.

Khandwala HM, McCutcheon IE, Flyvbjerg A, Friend KE (2000) The effects of insulin-like growth factors on tumorigenesis and neoplastic growth. Endocr Rev 21:215–244CrossRef

14.

Giovannucci E (2001) Insulin, insulin-like growth factors and colon cancer: a review of the evidence. J Nutr 131:3109S–3120SPubMed

15.

Reinmuth N, Liu W, Fan F, Jung YD, Ahmad SA, Stoeltzing O, Bucana CD, Radinsky R, Ellis LM (2002) Blockade of insulin-like growth factor I receptor function inhibits growth and angiogenesis of colon cancer. Clin Cancer Res 8:3259–3269

16.

Blakesley VA, Scrimgeour A, Esposito D, LeRoith D (1996) Signaling via the insulin-like growth factor-I receptor: does it differ from insulin receptor signaling? Cytokine Growth Factor Rev 7:153–159CrossRef

17.

LeRoith D, Roberts J (2003) The insulin-like growth factor system and cancer. Cancer Lett 195:127–137

18.

Kim HS, Nagalla SR, Oh Y, Wilson E, Roberts CT Jr, Rosenfeld RG (1997) Identification of a family of low-affinity insulin-like growth factor binding proteins (IGFBPs): characterization of connective tissue growth factor as a member of the IGFBP superfamily. Proc Natl Acad Sci USA 94:12981–12986CrossRef

19.

Kostecka Y, Blahovec J (1999) Insulin-like growth factor binding proteins and their functions (minireview). Endocr Regul 33:90–94

20.

Baxter RC, Binoux MA, Clemmons DR, Conover CA, Drop SLS, Holly JMP, Mohan S, Oh Y, Rosenfeld RG (1998) Recommendations for nomenclature of the insulin-like growth factor binding protein superfamily. J Clin Endocrinol Metab 83:3213CrossRef

21.

Mazerbourg S, Callebaut I, Zapf J, Mohan S, Overgaard M, Monget P (2004) Update on IGFBP-4: regulation of IGFBP-4 levels and functions, in vitro and in vivo. Growth Horm IGF Res 14:71–84CrossRef

22.

Baxter RC (2000) Insulin-like growth factor (IGF)-binding proteins: interactions with IGFs and intrinsic bioactivities. Am J Physiol Endocrinol Metab 278:E967–E976PubMed

23.

Zazzi H, Nikoshkov A, Hall K, Luthman H (1998) Structure and transcription regulation of the human insulin-like growth factor binding protein 4 gene (IGFBP4). Genomics 49:401–410CrossRef

24.

Sandhu MS, Dunger DB, Giovannucci EL (2002) Insulin, insulin-like growth factor-I (IGF-I), IGF binding proteins, their biologic interactions, and colorectal cancer. J Natl Cancer Inst 94:972–980

25.

Remacle-Bonnet MM, Garrouste FL, Pommier GJ (1997) Surface-bound plasmin induces selective proteolysis of insulin-like-growth-factor (IGF)-binding protein-4 (IGFBP-4) and promotes autocrine IGF-II bio-availability in human colon-carcinoma cells. Int J Cancer 72:835–843CrossRef

26.

Baciuchka M, Remacle-Bonnet M, Garrouste F, Favre R, Sastre B, Pommier G (1998) Insulin-like growth factor (IGF)-binding protein-3 (IGFBP-3) proteolysis in patients with colorectal cancer: possible association with the metastatic potential of the tumor. Int J Cancer 79:460–467

27.

Kuemmerle JF, Teng B (2000) Regulation of IGFBP-4 levels in human intestinal muscle by an IGF-I-activated, confluence-dependent protease. Am J Physiol Gastrointest Liver Physiol 279:G975–G982

28.

Palmqvist R, Stattin P, Rinaldi S, Biessy C, Stenling R, Riboli E, Hallmans G, Kaaks R (2003) Plasma insulin, IGF-binding proteins-1 and -2 and risk of colorectal cancer: a prospective study in northern Sweden. Int J Cancer 107:89–93CrossRef

29.

Kaaks R, Toniolo P, Akhmedkhanov A, Lukanova A, Biessy C, Dechaud H, Rinaldi S, Zeleniuch-Jacquotte A, Shore RE, Riboli E (2000) Serum C-peptide, insulin-like growth factor (IGF)-I, IGF-binding proteins, and colorectal cancer risk in women. J Natl Cancer Inst 92:1592–1600CrossRef

30.

Nomura AM, Stemmermann GN, Lee J, Pollak MN (2003) Serum insulin-like growth factor I and subsequent risk of colorectal cancer among Japanese-American men. Am J Epidemiol 158:424–431CrossRef

31.

Teramukai S, Rohan T, Lee KY, Eguchi H, Oda T, Kono S (2002) Insulin-like growth factor (IGF)-I, IGF-binding protein-3 and colorectal adenomas in Japanese men. Jpn J Cancer Res 93:1187–1194

32.

Renehan AG, Zwahlen M, Minder C, O’Dwyer ST, Shalet SM, Egger M (2004) Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet 363:1346–1353CrossRef

33.

Renehan AG, Jones J, O’Dwyer ST, Shalet SM (2003) Determination of IGF-I, IGF-II, IGFBP-2, and IGFBP-3 levels in serum and plasma: comparisons using the Bland-Altman method. Growth Horm IGF Res 13:341–346CrossRef

34.

Rosenfeld RG (2003) Insulin-like growth factors and the basis of growth. N Engl J Med 349:2184–2186CrossRef

35.

Reinmuth N, Fan F, Liu W, Parikh AA, Stoeltzing O, Jung YD, Bucana CD, Radinsky R, Gallick GE, Ellis LM (2002) Impact of insulin-like growth factor receptor-I function on angiogenesis, growth, and metastasis of colon cancer. Lab Invest 82:1377–1389

36.

Wu Y, Yakar S, Zhao L, Hennighausen L, LeRoith D (2002) Circulating insulin-like growth factor-I levels regulate colon cancer growth and metastasis. Cancer Res 62:1030–1035

37.

Akagi Y, Liu W, Zebrowski B, Xie K, Ellis LM (1998) Regulation of vascular endothelial growth factor expression in human colon cancer by insulin-like growth factor-I. Cancer Res 58:4008–4014

38.

Fukuda R, Hirota K, Fan F, Jung YD, Ellis LM, Semenza GL (2002) Insulin-like growth factor 1 induces hypoxia-inducible factor 1-mediated vascular endothelial growth factor expression, which is dependent on MAP kinase and phosphatidylinositol 3-kinase signaling in colon cancer cells. J Biol Chem 277:38205–38211CrossRef

39.

Collard TJ, Guy M, Butt AJ, Perks CM, Holly JMP, Paraskeva C, Williams AC (2003) Transcriptional upregulation of the insulin-like growth factor binding protein IGFBP-3 by sodium butyrate increases IGF-independent apoptosis in human colonic adenoma-derived epithelial cells. Carcinogenesis 24:393–401CrossRef

40.

Freier S, Weiss O, Eran M, Flyvbjerg A, Dahan R, Nephesh I, Safra T, Shiloni E, Raz I (1999) Expression of the insulin-like growth factors and their receptors in adenocarcinoma of the colon. Gut 44:704–708PubMed

41.

Ewton DZ, Kansra S, Lim S, Friedman E (2002) Insulin-like growth factor-I has a biphasic effect on colon carcinoma cells through transient inactivation of forkhead1, initially mitogenic, then mediating growth arrest and differentiation. Int J Cancer 98:665–673CrossRef

42.

Smith GD, Gunnell D, Holly J (2000) Cancer and insulin-like growth factor-I. A potential mechanism linking the environment with cancer risk. BMJ 321:847–848CrossRef

43.

Zarrilli R, Pignata S, Romano M, Gravina A, Casola S, Bruni CB, Acquaviva AM (1994) Expression of insulin-like growth factor (IGF)-II and IGF-I receptor during proliferation and differentiation of CaCo-2 human colon carcinoma cells. Cell Growth Differ 5:1085–1091

44.

Hassan AB, Macaulay VM (2002) The insulin-like growth factor system as a therapeutic target in colorectal cancer. Ann Oncol 13:349–356CrossRef

45.

Manousos O, Souglakos J, Bosetti C, Tzonou A, Chatzidakis V, Trichopoulos D, Adami HO, Mantzoros C (1999) IGF-I and IGF-II in relation to colorectal cancer. Int J Cancer 83:15–17CrossRefPubMed

46.

Howarth GS (2003) Insulin-like growth factor-I and the gastrointestinal system: therapeutic indications and safety implications. J Nutr 133:2109–2112

47.

Ouban A, Muraca P, Yeatman T, Coppola D (2003) Expression and distribution of insulin-like growth factor-1 receptor in human carcinomas. Human Pathol 34:803–808CrossRef

48.

Hakam A, Yeatman TJ, Lu L, Mora L, Marcet G, Nicosia SV, Karl RC, Coppola D (1999) Expression of insulin-like growth factor-1 receptor in human colorectal cancer. Human Pathol 30:1128–1133CrossRef

49.

Adenis A, Peyrat JP, Hecquet B, Delobelle A, Depadt G, Quandalle P, Bonneterre J, Demaille A (1995) Type I insulin-like growth factor receptors in human colorectal cancer. Eur J Cancer 31A:50–55CrossRef

50.

Wang D, Patil S, Li W, Humphrey LE, Brattain MG, Howell GM (2002) Activation of the TGFalpha autocrine loop is downstream of IGF-I receptor activation during mitogenesis in growth factor dependent human colon carcinoma cells. Oncogene 21:2785–2796CrossRefPubMed

51.

Garrouste F, Remacle-Bonnet M, Culouscou JM, Marvaldi J, Pommier G (1991) Type-II insulin-like growth-factor receptor in conditioned medium from HT-29 human colon carcinoma cell line. Int J Cancer 47:760–764

52.

Guo YS, Jin GF, Townsend CM Jr, Zhang T, Sheng HM, Beauchamp RD, Thompson JC (1995) Insulin-like growth factor-II expression in carcinoma in colon cell lines: implications for autocrine actions. J Am Coll Surg 181:145–154

53.

Leng SL, Leeding KS, Gibson PR, Bach LA (2001) Insulin-like growth factor-II renders LIM 2405 human colon cancer cells resistant to butyrate-induced apoptosis: a potential mechanism for colon cancer cell survival in vivo. Carcinogenesis 22:1625–1631CrossRef

54.

Weber MM, Fottner C, Liu SB, Jung MC, Engelhardt D, Baretton GB (2002) Overexpression of the insulin-like growth factor I receptor in human colon carcinomas. Cancer 95:2086–2095CrossRef

55.

Feldser D, Agani F, Iyer NV, Pak B, Ferreira G, Semenza GL (1999) Reciprocal positive regulation of hypoxia-inducible factor 1alpha and insulin-like growth factor 2. Cancer Res 59:3915–3918

56.

Michell NP, Langman MJ, Eggo MC (1997) Insulin-like growth factors and their binding proteins in human colonocytes: preferential degradation of insulin-like growth factor binding protein 2 in colonic cancers. Br J Cancer 76:60–66PubMed

57.

Jirtle RL (2004) IGF2 loss of imprinting: a potential heritable risk factor for colorectal cancer. Gastroenterology 126:1190–1193CrossRef

58.

Brenton JD, Viville S, Surani MA (1995) Genomic imprinting and cancer. Cancer Surv 25:161–171

59.

Hu JF, Vu TH, Hoffman AR (1996) Promoter-specific modulation of insulin-like growth factor II genomic imprinting by inhibitors of DNA methylation. J Biol Chem 271:18253–18262CrossRef

60.

Haig D, Graham C (1991) Genomic imprinting and the strange case of the insulin-like growth factor II receptor. Cell 64:1045–1046CrossRef

61.

Cruz-Correa M, Cui H, Giardiello FM, Powe NR, Hylind L, Robinson A, Hutcheon DF, Kafonek DR, Brandenburg S, Wu Y, He X, Feinberg AP (2004) Loss of imprinting of insulin growth factor II gene: a potential heritable biomarker for colon neoplasia predisposition. Gastroenterology 126:964–970CrossRef

62.

Nakagawa H, Chadwick RB, Peltomaki P, Plass C, Nakamura Y, de La Chapelle A (2001) Loss of imprinting of the insulin-like growth factor II gene occurs by biallelic methylation in a core region of H19-associated CTCF-binding sites in colorectal cancer. Proc Natl Acad Sci USA 98:591–596CrossRef

63.

Cui H, Onyango P, Brandenburg S, Wu Y, Hsieh CL, Feinberg AP (2002) Loss of imprinting in colorectal cancer linked to hypomethylation of H19 and IGF2. Cancer Res 62:6442–6446

64.

Cui H, Cruz-Correa M, Giardiello FM, Hutcheon DF, Kafonek DR, Brandenburg S, Wu Y, He X, Powe NR, Feinberg AP (2003) Loss of IGF2 imprinting: a potential marker of colorectal cancer risk. Science 299:1753–1755CrossRef

65.

Ma J, Giovannucci E, Pollak M, Chan JM, Gaziano JM, Willett W, Stampfer MJ (2001) Milk intake, circulating levels of insulin-like growth factor-I, and risk of colorectal cancer in men. J Natl Cancer Inst 93:1330–1336CrossRef

66.

Allen NE, Appleby PN, Davey GK, Kaaks R, Rinaldi S, Key TJ (2002) The associations of diet with serum insulin-like growth factor I and its main binding proteins in 292 women meat-eaters, vegetarians, and vegans. Cancer Epidemiol Biomarkers Prev 11:1441–1448

67.

Norat T, Riboli E (2003) Dairy products and colorectal cancer. A review of possible mechanisms and epidemiological evidence. Eur J Clin Nutr 57:1–17CrossRefPubMed

68.

Yasumaru M, Tsuji S, Tsujii M, Irie T, Komori M, Kimura A, Nishida T, Kakiuchi Y, Kawai N, Murata H, Horimoto M, Sasaki Y, Hayashi N, Kawano S, Hori M (2003) Inhibition of angiotensin II activity enhanced the antitumor effect of cyclooxygenase-2 inhibitors via insulin-like growth factor I receptor pathway. Cancer Res 63:6726–6734

69.

Di Popolo A, Memoli A, Apicella A, Tuccillo C, di Palma A, Ricchi P, Acquaviva AM, Zarrilli R (2000) IGF-II/IGF-I receptor pathway up-regulates COX-2 mRNA expression and PGE2 synthesis in Caco-2 human colon carcinoma cells. Oncogene 19:5517–5524CrossRef

70.

Hoflich A, Lahm H, Blum W, Kolb H, Wolf E (1998) Insulin-like growth factor-binding protein-2 inhibits proliferation of human embryonic kidney fibroblasts and of IGF-responsive colon carcinoma cell lines. FEBS Lett 434:329–334CrossRef

71.

Pommier GJ, Garrouste FL, el Atiq F, Roccabianca M, Marvaldi JL, Remacle-Bonnet MM (1992) Potential autocrine role of insulin-like growth factor II during suramin-induced differentiation of HT29-D4 human colonic adenocarcinoma cell line. Cancer Res 52:3182–3188

72.

Nishimura A, Fujimoto M, Oguchi S, Fusunyan RD, MacDermott RP, Sanderson IR (1998) Short-chain fatty acids regulate IGF-binding protein secretion by intestinal epithelial cells. Am J Physiol 275:E55–E63

73.

Kelly RG, Nally K, Shanahan F, O’Connell J (2002) Type I insulin-like growth factor receptor expression on colorectal adenocarcinoma cell lines is decreased in response to the chemopreventive agent N-acetyl-l-cysteine. Ann NY Acad Sci 973:555–558

74.

Kim EJ, Kang IJ, Cho HJ, Kim WK, Ha YL, Park JHY (2003) Conjugated linoleic acid downregulates insulin-like growth factor-I receptor levels in HT-29 human colon cancer cells. J Nutr 133:2675–2681

75.

Perer ES, Madan AK, Shurin A, Zakris E, Romeguera K, Pang Y, Beech DJ (2000) Insulin-like growth factor I receptor antagonism augments response to chemoradiation therapy in colon cancer cells. J Surg Res 94:1–5CrossRef

76.

Meyerhardt JA, Catalano PJ, Haller DG, Mayer RJ, Macdonald JS, Benson AB III, Fuchs CS (2003) Impact of diabetes mellitus on outcomes in patients with colon cancer. J Clin Oncol 21:433–440CrossRef

77.

Miraki-Moud F, Jenkins PJ, Fairclough PD, Jordan S, Bustin SA, Jones AM, Lowe DG, Monson JP, Grossman AB, Besser GM, Camacho-Hubner C (2001) Increased levels of insulin-like growth factor binding protein-2 in sera and tumours from patients with colonic neoplasia with and without acromegaly. Clin Endocrinol (Oxf) 54:499–508CrossRef

78.

Jenkins PJ, Frajese V, Jones AM, Camacho-Hubner C, Lowe DG, Fairclough PD, Chew SL, Grossman AB, Monson JP, Besser GM (2000) Insulin-like growth factor I and the development of colorectal neoplasia in acromegaly. J Clin Endocrinol Metab 85:3218–3221CrossRef

79.

Guo YS, Narayan S, Yallampalli C, Singh P (1992) Characterization of insulinlike growth factor I receptors in human colon cancer. Gastroenterology 102:1101–1108

80.

Singh P, Dai B, Yallampalli C, Xu Z (1994) Expression of IGF-II and IGF-binding proteins by colon cancer cells in relation to growth response to IGFs. Am J Physiol 267:G608–G617

81.

Oguchi S, Walker WA, Sanderson IR (1993) Insulin-like growth factor binding protein profile secreted by human intestinal epithelial cells varies with polarity. Biochem Biophys Res Commun 196:789–793CrossRef

82.

Remacle-Bonnet M, Garrouste F, el Atiq F, Roccabianca M, Marvaldi J, Pommier G (1992) Des-(1–3)-IGF-I, an insulin-like growth factor analog used to mimic a potential IGF-II autocrine loop, promotes the differentiation of human colon-carcinoma cells. Int J Cancer 52:910–917

83.

Mishra L, Bass B, Ooi BS, Sidawy A, Korman L (1998) Role of insulin-like growth factor-I (IGF-I) receptor, IGF-I, and IGF binding protein-2 in human colorectal cancers. Growth Horm IGF Res 8:473–479

84.

Singh P, Dai B, Yallampalli U, Lu X, Schroy PC (1996) Proliferation and differentiation of a human colon cancer cell line (CaCo2) is associated with significant changes in the expression and secretion of insulin-like growth factor (IGF) IGF-II and IGF binding protein-4: role of IGF-II. Endocrinology 137:1764–1774CrossRef

85.

Zhang Y, Wick DA, Seetharam B, Dahms NM (1995) Expression of IGF-II and IGF binding proteins in differentiating human intestinal Caco-2 cells. Am J Physiol Endocrinol Metab 269:E804–E813

86.

Hunt KJ, Toniolo P, Akhmedkhanov A, Lukanova A, Dechaud H, Rinaldi S, Zeleniuch-Jacquotte A, Shore RE, Riboli E, Kaaks R (2002) Insulin-like growth factor II and colorectal cancer risk in women. Cancer Epidemiol Biomarkers Prev 11:901–905

87.

Firth SM, Baxter RC (2002) Cellular actions of the insulin-like growth factor binding proteins. Endocr Rev 23:824–854CrossRefPubMed

88.

Dai B, Widen SG, Mifflin R, Singh P (1997) Cloning of the functional promoter for human insulin-like growth factor binding protein-4 gene: endogenous regulation. Endocrinology 138:332–343CrossRef

89.

Hoeflich A, Reisinger R, Lahm H, Kiess W, Blum WF, Kolb HJ, Weber MM, Wolf E (2001) Insulin-like growth factor-binding protein 2 in tumorigenesis: protector or promoter? Cancer Res 61:8601–8610

90.

Reeve JG, Kirby LB, Brinkman A, Hughes SA, Schwander J, Bleehen NM (1992) Insulin-like growth-factor-binding protein gene expression and protein production by human tumour cell lines. Int J Cancer 51:818–821

91.

Michell NP, Dent S, Langman MJ, Eggo MC (1997) Insulin-like growth factor binding proteins as mediators of IGF-I effects on colon cancer cell proliferation. Growth Factors 14:269–277

92.

Renehan AG, Jones J, Potten CS, Shalet SM, O’Dwyer ST (2000) Elevated serum insulin-like growth factor (IGF)-II and IGF binding protein-2 in patients with colorectal cancer. Br J Cancer 83:1344–1350CrossRef

93.

MacDonald RG, Schaffer BS, Kang IJ, Hong SM, Kim EJ, Park JH (1999) Growth inhibition and differentiation of the human colon carcinoma cell line, Caco-2, by constitutive expression of insulin-like growth factor binding protein-3. J Gastroenterol Hepatol 14:72–78CrossRef

94.

Kansra S, Ewton DZ, Wang J, Friedman E (2000) IGFBP-3 mediates TGF beta 1 proliferative response in colon cancer cells. Int J Cancer 87:373–378CrossRef

95.

Williams AC, Collard TJ, Perks CM, Newcomb P, Moorghen M, Holly JM, Paraskeva C (2000) Increased p53-dependent apoptosis by the insulin-like growth factor binding protein IGFBP-3 in human colonic adenoma-derived cells. Cancer Res 60:22–27

96.

Giovannucci E, Pollak MN, Platz EA, Willett WC, Stampfer MJ, Majeed N, Colditz GA, Speizer FE, Hankinson SE (2000) A prospective study of plasma insulin-like growth factor-1 and binding protein-3 and risk of colorectal neoplasia in women. Cancer Epidemiol Biomarkers Prev 9:345–349

97.

Oh Y, Nagalla SR, Yamanaka Y, Kim HS, Wilson E, Rosenfeld RG (1996) Synthesis and characterization of insulin-like growth factor-binding protein (IGFBP)-7. Recombinant human mac25 protein specifically binds IGF-I and -II. J Biol Chem 271:30322–30325CrossRef

98.

Miyamoto S, Yano K, Sugimoto S, Ishii G, Hasebe T, Endoh Y, Kodama K, Goya M, Chiba T, Ochiai A (2004) Matrix metalloproteinase-7 facilitates insulin-like growth factor bioavailability through its proteinase activity on insulin-like growth factor binding protein 3. Cancer Res 64:665–671PubMed

99.

Monitto CL, Berkowitz D, Lee KM, Pin S, Li D, Breslow M, O’Malley B, Schiller M (2001) Differential gene expression in a murine model of cancer cachexia. Am J Physiol Endocrinol Metab 281:E289–E297

100.

Diehl D, Hoeflich A, Wolf E, Lahm H (2004) Insulin-like growth factor (IGF)-binding protein-4 inhibits colony formation of colorectal cancer cells by IGF-independent mechanisms. Cancer Res 64:1600–1603PubMed

101.

Butt AJ, Dickson KA, McDougall F, Baxter RC (2003) Insulin-like growth factor-binding protein-5 inhibits the growth of human breast cancer cells in vitro and in vivo. J Biol Chem 278:29676–29685CrossRef

102.

Schneider MR, Wolf E, Hoeflich A, Lahm H (2002) IGF-binding protein 5: flexible player in the IGF system and effector on its own. J Endocrinol 172:423–440PubMed

103.

Oh YS, Kim EJ, Schaffer BS, Kang YH, Binderup L, MacDonald RG, Park JH (2001) Synthetic low-calcaemic vitamin D(3) analogues inhibit secretion of insulin-like growth factor II and stimulate production of insulin-like growth factor-binding protein-6 in conjunction with growth suppression of HT-29 colon cancer cells. Mol Cell Endocrinol 183:141–149CrossRef

104.

Kim EJ, Kim WY, Kang YH, Ha YL, Bach LA, Park JHY (2000) Inhibition of CACO-2 cell proliferation by (n-3) fatty acids: possible mediation by increased secretion of insulin-like growth factor binding protein-6. Nutr Res 20:1409–1421CrossRef

105.

Shao L, Huang Q, Luo M, Lai M (2003) Detection of the differentially expressed gene IGFBP-rP1 and analysis of its relationship to fasting glucose in Chinese colorectal cancer patients. Endocr Relat Cancer 11:141–148CrossRef

106.

Rajaram S, Baylink DJ, Mohan S (1997) Insulin-like growth factor-binding proteins in serum and other biological fluids: regulation and functions. Endocr Rev 18:801–831CrossRefPubMed

107.

Degeorges A, Wang F, Frierson HF Jr, Seth A, Sikes RA (2000) Distribution of IGFBP-rP1 in normal human tissues. J Histochem Cytochem 48:747–754

108.

Ma J, Pollak M, Giovannucci E, Chan JM, Tao Y, Hennekens C, Stampfer MJ (2000) A prospective study of plasma levels of insulin-like growth factor I (IGF-I) and IGF-binding protein-3, and colorectal cancer risk among men. Growth Horm IGF Res 10 [Suppl A]:S28–S29CrossRef

109.

Probst-Hensch NM, Yuan JM, Stanczyk FZ, Gao YT, Ross RK, Yu MC (2001) IGF-1, IGF-2 and IGFBP-3 in prediagnostic serum: association with colorectal cancer in a cohort of Chinese men in Shanghai. Br J Cancer 85:1695–1699CrossRef

110.

Renehan AG, Painter JE, Atkin WS, Potten CS, Shalet SM, O’Dwyer ST (2001) High-risk colorectal adenomas and serum insulin-like growth factors. Br J Surg 88:107–113CrossRefPubMed

111.

El Atiq F, Garrouste F, Remacle-Bonnet M, Sastre B, Pommier G (1994) Alterations in serum levels of insulin-like growth factors and insulin-like growth-factor-binding proteins in patients with colorectal cancer. Int J Cancer 57:491–497

112.

Renehan AG, Toogood AA, Ryder WD, Jones J, Potten CS, O’Dwyer ST, Shalet SM (2001) Paradoxical elevations in serum IGF-II and IGF binding protein-2 in acromegaly: insights into the regulation of these peptides. Clin Endocrinol (Oxf) 55:469–475CrossRef

113.

Renehan AG, Painter JE, O’Halloran D, Atkin WS, Potten CS, O’Dwyer ST, Shalet SM (2000) Circulating insulin-like growth factor II and colorectal adenomas. J Clin Endocrinol Metab 85:3402–3408CrossRefPubMed

114.

Culouscou JM, Shoyab M (1991) Purification of a colon cancer cell growth inhibitor and its identification as an insulin-like growth factor binding protein. Cancer Res 51:2813–2819

115.

Saksena M, Miraki-Moud F, King P, Camacho-Hubner C (2002) Effect of insulin-like growth factor binding protein-3 (IGFBP-3) on colon cancer epithelial cells growth and apoptosis [abstract]. Endocr Abstr 4:OC15

116.

David TM, Khalaf S, Davies D, Bustin S, Jenkins PJ (2004) The influence of IGFBP-3 on colonic epithelial cell proliferation and apoptosis [abstract]. Endocr Abstr 2:P22

117.

Kim EJ, Kang YH, Schaffer BS, Bach LA, MacDonald RG, Park JH (2002) Inhibition of Caco-2 cell proliferation by all-trans retinoic acid: role of insulin-like growth factor binding protein-6. J Cell Physiol 190:92–100CrossRef

118.

Kim EJ, Holthuizen PE, Park HS, Ha YL, Jung KC, Park JH (2002) Trans-10,cis-12-conjugated linoleic acid inhibits Caco-2 colon cancer cell growth. Am J Physiol Gastrointest Liver Physiol 283:G357–G367

119.

Kirman I, Cekic V, Poltaratskaia N, Asi Z, Bessler M, Huang EH, Forde KA, Whelan RL (2002) Plasma from patients undergoing major open surgery stimulates in vitro tumor growth: lower insulin-like growth factor binding protein 3 levels may, in part, account for this change. Surgery 132:186–192CrossRefPubMed

120.

Cho HJ, Lee HS, Chung CK, Kang YH, Ha YL, Park HS, Park JH (2003) Trans-10, cis-12 conjugated linoleic acid reduces insulin-like growth factor-II secretion in HT-29 human colon cancer cells. J Med Food 6:193–199CrossRef

Titel: The role of the insulin-like growth factor system in colorectal cancer: review of current knowledge
verfasst von: Rajaraman Durai
Wenxuan Yang
Sharmila Gupta
Alexander M. Seifalian
Marc C. Winslet
Publikationsdatum: 01.05.2005
Verlag: Springer-Verlag
Erschienen in: International Journal of Colorectal Disease / Ausgabe 3/2005
Print ISSN: 0179-1958
Elektronische ISSN: 1432-1262
DOI: https://doi.org/10.1007/s00384-004-0675-4

Neu im Fachgebiet Chirurgie

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren.

Wie sieht der OP der Zukunft aus?

04.05.2024 DCK 2024 Kongressbericht

Der OP in der Zukunft wird mit weniger Personal auskommen – nicht, weil die Technik das medizinische Fachpersonal verdrängt, sondern weil der Personalmangel es nötig macht.

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Recycling im OP – möglich, aber teuer

02.05.2024 DCK 2024 Kongressbericht

Auch wenn sich Krankenhäuser nachhaltig und grün geben – sie tragen aktuell erheblich zu den CO₂-Emissionen bei und produzieren jede Menge Müll. Ein Pilotprojekt aus Bonn zeigt, dass viele Op.-Abfälle wiederverwertet werden können.

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Aktuelle BDC Leitlinien-Webinare

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare

CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare

CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske

Dr. med. Benjamin Meyknecht

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare

CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric

Springer Medizin

Abstract

Background

Discussion

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2005

Results of treatment of distal rectal carcinoma since the introduction of total mesorectal excision: a single unit experience, 1994–2003

A case of colorectal carcinoma in adenoma analyzed by a cDNA array

Apoptosis in the intestinal mucosa of patients with inflammatory bowel disease: evidence of altered expression of FasL and perforin cytotoxic pathways

Microscopic spread of low rectal cancer in regions of the mesorectum: detailed pathological assessment with whole-mount sections

Radical surgery for colorectal metastatic melanoma

May 2005

Update Chirurgie